Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxothiazolidinecarboxylic acid (also known as procysteine or OTC) is a small molecule prodrug of cysteine and an antioxidant. It is metabolized intracellularly to cysteine, thereby stimulating glutathione synthesis. This mechanism supports cellular antioxidant defenses by increasing the availability of glutathione, a key endogenous antioxidant. Oxothiazolidinecarboxylic acid has been investigated for its potential therapeutic effects in conditions associated with oxidative stress and glutathione deficiency. Clinical studies have explored its use in HIV infection and vascular calcification due to its ability to replenish intracellular cysteine and maintain glutathione levels[2][3][6]. It has also been used as an ingredient in personal care products due to its safety profile[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oxothiazolidinecarboxylic acid.